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Abstract: Chromosomal rearrangements involving the ROS1 
receptor tyrosine kinase have been described in a variety of human 
malignancies including non–small-cell lung cancer (NSCLC), 
cholangiocarcinoma and glioblastoma multiforme. Recently, clini-
copathologic characteristics of c-ros oncogene 1, receptor tyrosine 
kinase (ROS1)-rearranged NSCLC patients have been described. 
Furthermore, anaplastic lymphoma kinase inhibitor, novel class of 
drugs targeting this tyrosine kinase receptor is currently under clini-
cal trial in this molecular subset of NSCLC patients. This review 
will focus on the current knowledge of ROS1 rearrangements in 
NSCLC, methods to detect ROS1 rearrangement, and targeting 
ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase 
inhibitors.
Key Words: Non–-small-cell lung cancer, Targeted therapy, ROS1, 
Anaplastic lymphoma kinase inhibitors, Crizotinib.
(J Thorac Oncol. 2012;7: 1625–1630)
The past decade has witnessed significant success with per-sonalized cancer therapy, and this paradigm shift has led 
to tremendous improvements in clinical outcomes in patients 
with molecularly defined subsets of tumors. Notably, the dis-
covery of a variety of molecular and genetic alternations in 
non–small-cell lung cancer (NSCLC) has provided the oppor-
tunity for targeted therapy, such as epidermal growth factor 
receptortyrosine kinase inhibitors (gefitinib and erlotinib) 
for activating EGFR mutations in NSCLC, and anaplastic 
lymphoma kinase (ALK) inhibitor (crizotinib) for NSCLC 
harboring ALK gene fusion. The  c-ros oncogene 1 (ROS1) 
receptor tyrosine kinase (RTK) has recently emerged as a 
potentially relevant therapeutic target in NSCLC. Here, our 
review focuses on the oncogenic role of aberrant ROS1 in 
NSCLC and targeting ROS1-rearranged NSCLC patients with 
ALK inhibitors.
ROS1 RECEPTOR STRUCTURE AND FUNCTION
v-ROS1 is an oncogene product of the avian sarcoma 
RNA tumor virus UR2.1 Wild-type ROS1 is located on chro-
mosome 6 and encodes full-length ROS1, a 2,347 amino 
acid transmembrane tyrosine kinase (TK) receptor consist-
ing of an extracellular ligand-binding domain composed of 
nine repeated fibronectin-like motifs, a short transmembrane 
domain, and an intracellular TK domain.2 Although very little 
is known of the extracellular domain function of this orphan 
receptor, the structural combination of ROS1 suggests its abil-
ity to directly couple extracellular adhesion-mediated events 
to tyrosine phosphorylation-based intracellular signaling. 
Using the Multiple Sequence Comparison by Log-Expression 
software, it has been found that there is a 49% amino acid 
homology between human ROS and ALK within the kinase 
domain3 and 77% identity at the adenosine triphosphate 
(ATP)-binding site.4
Dysregulated ROS1 may occur as a result of ROS1 
gene fusion, overexpression, or mutations. Aberrant ROS1 
kinase activity leads to activated downstream signaling of 
several oncogenic pathways including the phosphoinosit-
ide-3 kinase/v-akt murine thymoma viral oncogene homo-
log 1 (AKT)/mechanistic target of rapamycin (serine/
threonine kinase) (mTOR), signal transducers and activa-
tors of transcription-3, RAS-MAPK/ERK, vav 3 guanine 
nucleotide exchange factor 1 (VAV3) and Src-homology 2 
domain-containing phosphatase (SHP)-1 and -2 pathways 
(Fig. 1).5,6 With the activation of ALK fusion proteins, the 
downstream signaling pathways are similar to ROS1 RTK 
activation with the involvement of the RAS-MAPK/ERK, 
Janus kinase 3-signal transducers and activators of tran-
scription-3, and phosphoinositide-3 kinase /Akt pathways, 
which control cell proliferation, survival, and cell cycling.7,8 
However, unlike the echinoderm microtubule-associated 
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protein-like 4 (EML4)-ALK gene fusion in which the 
coiled-coil domain within echinoderm microtubule-asso-
ciated protein-like 4 mediates the constitutive dimerization 
resulting in aberrant constitutive activity,9 protein dimer-
ization domains have not been described in ROS1 fusion 
receptor tyrosine kinases.5
FIGURE 1. ROS1 signaling pathways. ROS1 engages multiple signalling pathways to exert its transformation activity. PLCγ, 
MAP kinase, IRS1 (signalling molecule to PI3K), VAV3, STATS, cytoskeleton and cell-to-cell interaction (β-integrin, tensin, α-, β-, 
δ-catenin, N-catenin) proteins can interact with ROS1, and phospohorylation of these proteins by ROS1 can lead to activation 
of the respective oncogenic pathways. ROS autophosphorylation sites are docking sites for the tyrosine phosphatases SHP-1 
and SHP, Src-homology 2 domain-containing phosphatase; ROS1, c-ros oncogene 1, receptor tyrosine kinase c-ros oncogene 1, 
receptor tyrosine kinase; PLCγ, phospholipase C, gamma; MAP, mitogen-activated protein kinase; IRS1, insulin receptor sub-
strate 1; VAV3, vav 3 guanine nucleotide exchange factor 1; STATS, signal transducers and activators of transcription-3; PDK1, 
pyruvate dehydrogenase kinase, isozyme 1; AKT (v-akt murine thymoma viral oncogene homolog 1); mTOR, mechanistic target 
of rapamycin (serine/threonine kinase); P13K, phosphoinositide-3 kinase; and RHO, rhodopsin.
TABLE 1. ROS1 Fusion Variants Described in Non–Small-Cell Lung Cancer
Fusion Variant
Chromosomal 
Translocation Lung Tumor Type
ROS1 Exon 
Breakpoint
Partner Exon 
Breakpoint Reference
CD74-ROS1 t(5;6) (q32;q22) Non–small-cell lung cancer 32
34
6
6
11
12,15
EZR-ROS1 Inv(6) (q22;q25.3) Adenocarcinoma 34 10 13
LRIG3-ROS1 t(6;12) (q22;q14.1) Adenocarcinoma 35 16 13
SDC4-ROS1 t(6;20) (q22;q12) Adenocarcinoma 32
34
2
2
13
13
SLC34A2-ROS1 t(4;6) (p15.2;q22) HCC78 cell line 32
34
4
4
12
12
TPM3-ROS1 t(1;6) (q21.2;q22) Adenocarcinoma 35 8 13
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ROS1 Fusion Genes
To date, seven distinct ROS1 gene fusions have been 
identified in solid tumors including fused in glioblastoma 
(FIG)-ROS1, CD74-ROS1, solute carrier family 34 (sodium 
phosphate), member 2 (SLC34A2)-ROS1, tropomyosin 3 
(TPM3)-ROS1, syndecan 4 (SDC4)-ROS1, ezrin (EZR)-ROS1, 
leucine-rich repeats, and immunoglobulin-like domains 3 
(LRIG3-ROS1) all of which encoded the same cytoplasmic 
portion of ROS1 TK domain. The break point of ROS1 with 
EZR is exon 34, TPM3, FIG, and LRIG3 is exon 35 whereas 
for CD74, SDC4, and SLC34A2 are exons 32 and 34. (Table1). 
All of the breakpoints in ROS1 allow the resulting fusion to 
retain the ROS1 kinase domain whereas with SDC4-ROS1, 
the ROS1 transmembrane domain is also retained.3 More 
recently, Govindan et al.9a have identified a novel ROS1 fusion, 
KDELR2 (endoplasmic reticulum protein retention receptor 
2) in a never smoker patient with NSCLC.
FIG-ROS1 fusion was first described in glioblas-
toma multiforme6,10 and subsequently in 8.7% of cholangio-
carcinoma tumors.11 The clinicopathologic characteristics 
of patients with glioblastoma multiforme and cholangio-
carcinoma harboring FIG-ROS1 is unknown. In NSCLC, 
SLC34A2-ROS1 and CD74-ROS1 were initially discovered in 
the HCC78 cell line and in a patient tumor, respectively.12
Down-regulation of SLC34A2-ROS1 inhibited cellular 
proliferation in HCC78 cells12 whereas more recently, the trans-
forming ability of FIG-ROS1 and TPM3-ROS1, SDC4-ROS1, 
SLC34A2-ROS1, CD74-ROS1, LRIG-ROS1, and EZR-ROS1 
was demonstrated in vivo by Gu et al.11 and Takeuchi et al.13
In a screen using fluorescence in situ hybridization 
(FISH) for ROS1 rearrangements, 1.7% of NSCLC patients 
(18 of 1073) harbored CD74-ROS1 or SLC34A2-ROS1 fusions, 
and ROS1 fusions were more likely in younger patients, never 
smokers with adenocarcinoma subtype.14 Of the 18 cases 
reported in this study, no fusion partner was identified in eight 
samples. Takeuchi et al.13 have reported ROS1 fusion genes 
in 0.9% NSCLC (13 of 1476) and 1.2% of patients (13 of 
1116) with adenocarcinomas. Four novel ROS1 gene fusions 
were reported: TPM3-ROS1, SDC4-ROS1, EZR-ROS1, and 
LRIG3-ROS1.13 In one case, no fusion partner was identified. 
In a study of East Asian never smokers with lung adenocarci-
noma, 1% (2 of 202) harbored ROS1 fusion.15
Using immunohistochemistry, and confirming the find-
ings by FISH and reverse transcriptase polymerase chain 
reaction (RT-PCR), Rimkunas et al.16 reported ROS1 was 
overexpressed in 1.6% of all lung NSCLC (9 of 556) and 3.3% 
of lung adenocarcinoma (8 of 246) from Chinese patients. The 
pattern of cellular localization of ROS1 protein was variable 
with diffuse cytoplasm, perinuclear aggregates, and membra-
nous and vesicular localization reported. It is interesting that, 
this is the first study to report a case of FIG-ROS1 in NSCLC.
On the basis of the studies described above, it can be 
stated that ROS1 fusions represent a unique molecular sub-
set of NSCLC with no overlap with other described onco-
gene drivers, and are rare with a frequency of 0.7% to 1.7% 
(Table 2) as compared with EGFR mutations (6%–33%)17 and 
ALK fusion (4%).18 There is overlap in the clinicopathologic 
characteristics between ROS1 and ALK rearrangement in 
NSCLC patients, namely in younger patients with a history of 
never smoking and adenocarcinoma subtype.
ROS1 Overexpressions and Mutations
Microarray analysis of NSCLC demonstrated signifi-
cantly elevated ROS1 expressions in 20% to 30% of cases, and 
elevated ROS1 expression was found to be part of a molecular 
signature for lung adenocarcinoma subtype.19–21 ROS1 muta-
tions have been reported in NSCLC22,23 and interestingly, 
they were in nonadenocarcinoma histologic subtypes. ROS1 
somatic mutations were also reported in very low frequen-
cies in cancers of the colon, ovary, breast, upper aerodigestive 
tract, and skin.22,24–26 The significance of these mutations is 
unknown. Overexpression of ROS1 has been reported in 33% 
to 56 % of glioblastoma and meningeal tumors.27–30
METHODS OF DETECTION FOR ALTERED ROS1
The first ROS1 translocations in human NSCLC 
(SLC34A2-ROS1 and CD74-ROS1) were discovered through 
a global survey of phosphotyrosine kinase signaling in 41 
NSCLC cell lines and more than 150 NSCLC tumor samples 
using an immunoaffinity phosphoproteomic profiling strat-
egy.12 More recently, a ROS1 break-apart FISH was used to 
screen for ROS1 rearrangements.14 As FISH provides no infor-
mation about the translocation partner, rapid amplification of 
complementary DNA assays and fusion-specific RT-PCR com-
bined with Sanger sequencing of the polymerase chain reaction 
products have been applied to identify ROS1 fusion variants in 
ROS1-positive screens. Validation of ROS1 fusions after their 
initial discovery was mostly performed using RT-PCR.10–12 
Immunohistochemistry with the D4D6 rabbit monoclonal 
antibody (Cell Signaling, Danvers, MA) that recognizes amino 
acids at the carboxyl terminus of human ROS1 has recently 
been reported to detect ROS1 fusions identified by ROS1 FISH 
analysis with high sensitivity and no false-positive identifica-
tion.16 ROS1 was not detectable using D4D6 in normal lung 
TABLE 2. Frequency of ROS1 Fusions in Non–Small-Cell 
Lung Cancer
Study
Method for Screening 
And Confirmation
Study Population 
(Sample Size)
Number of ROS1 
Fusions (%)
Rikova  
et al.12
Phosphoproteomics
RT-PCR
Chinese (150) 1 (0.7%)
Bergethon 
et al.14
FISH (break-apart)
RT-PCR
Total (1073)
Asian (45)
Non-Asian (942)
Not available (86)
18 (1.7%)
5 (11.1%)
13 (1.4%)
0 (0%)
Li et al.15 RT-PCR
Direct sequencing
Chinese (202)a 2 (1. 0%)
Takeuchi  
et al.13
FISH (break-apart)
RT-PCR
FISH (fusion-specific)
Japanese (1476) 13 (0.9%)
Rimkunas 
et al.16
IHC screen
RT-PCR
Chinese (556) 9 (1.6%)
aAll were adenocarcinoma, never smokers
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; RT-PCR: 
reverse transcriptase polymerase chain reaction.
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tissues, although in rare cases, non-neoplastic cells, such as 
macrophages and bronchial epithelial cells, displayed expres-
sion. This is in comparison to a previous report according 
to which high levels of ROS1 are expressed in lung normal 
tissue.5 As only 25% of cases (138 of 556) underwent ROS1 
FISH analysis in this study, the false-negative rate of this assay 
remains to be clarified. Results from this study by Rimkunas 
et al.16 suggest ROS1 immunohistochemistry may be a useful 
method for screening for the low frequency of patients with 
NSCLC harboring ROS1 fusions. Advantages of an immuno-
histochemistry assay include a more rapid turnaround time 
and analysis can be performed on a small amount of tissue. In 
contrast, FISH requires more specialized equipment, is more 
costly, and signal fadeout occurs over time. In addition, next-
generation sequencing31,32 and chromogenic in situ hybridiza-
tion33,34 approaches may have further advantages in detecting 
ROS1 rearrangement, as shown in ALK-rearranged NSCLC.
Targeting ROS1-Rearranged NSCLC 
Patients with ALK Inhibitors
Given the high homology in the kinase domains of 
ROS1 and ALK, ALK inhibitors were tested efficacious 
against ROS1-positive cell lines and tumors (Table 3). In pre-
clinical studies, TAE684, an ALK inhibitor, demonstrated in 
vitro activity against HCC78 cell lines,35 attenuated phosphor-
ylation of downstream ROS1 signaling, and induced apoptosis 
in FIG-ROS–positive BaF cells.11 In silico modeling suggests 
the drug–amino acid interactions between TAE684 and ROS1 
kinase domain is as strong as with the ALK kinase domain.3 
A phase I trial (NCT00585195) of crizotinib was amended 
to include ROS1-positive advanced-stage NSCLC patients. 
Preliminary results in this subset of 14 evaluable patients 
reported a response rate of 57% with a disease control rate 
TABLE 3. IC50 of Selected ROS1 Tyrosine Kinase Inhibitors
Compound IC
50
Reference
Crizotinib 1.7 nM 36
AP26113 1.9 nM 37
WZ-5–126 8.2 nM 35
TAE684 10 nM 35
KIST301072 199 nM 38
KIST301080 209 nM 39
FIGURE 2. ROS1 fusion variants described in non–small-cell lung cancer. The breakpoints of ROS1 are located at exons 32 
(e32), 34 (e34), and 35 (e35). All the ROS1 variants harbor the kinase domain whereas the exon 32 breakpoint allows the 
resulting fusion variants to harbor the TM. In the fusion partners, orange and dark green represent coiled-coil and transmem-
brane domains, respectively. TM, transmembrane domain; and PD2,.
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of 79% at 8 weeks.4 Other early-phase studies that include 
patients with tumors harboring ROS1 fusions of second-gen-
eration ALK inhibitors such as AP26113 (NCT01449461) and 
ASP3026 (NCT01284192) are ongoing (Table 4).
Perspective, Future Direction and Conclusion
Although rare, the evidence supports ROS1 fusions as 
a valid therapeutic target in a molecularly defined subset of 
NSCLC patients. Results from NCT00585195 are eagerly 
awaited. Future work will include testing the sensitivity of 
the ROS1 fusion variants to crizotinib. Further issues to be 
addressed include the optimal method to detect clinically 
relevant ROS1, exact definition of ROS1-positive tumors for 
treatment stratification and diagnosis, characterization of 
downstream signaling pathways in ROS1 fusion tumors, and 
understanding the resistance to ROS1 RTK inhibitors. 
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